Bisphosphonates and Bone Diseases
Those who are diagnosed with osteoporosis should know that bisphosphonates can help prevent bone loss. This is the most common drug used to treat osteoporosis. Bisphosphonates are also used to treat other bone disorders.
Common side effects
Taking bisphosphonates to treat osteoporosis can cause a lot of side effects. The most common side effect of bisphosphonates is nausea and abdominal pain. It can also affect your eyesight. Some people also experience flu-like symptoms when they take bisphosphonates.
If you take bisphosphonates, you should be careful not to take more than the recommended amount. You also need to tell your doctor about any medicines you take. For example, if you take ibuprofen, aspirin, or other painkillers, they can irritate the esophagus when you take bisphosphonates. Taking bisphosphonates may also cause dental problems such as toothache. If dental problems occur, you should stop taking bisphosphonates.
Bisphosphonates should be taken at least two hours before food. If you miss a tablet, you should take it when you remember. If you take a bisphosphonate once a month, you should not take two tablets in the same week. When you take bisphosphonates, you should drink plenty of water.
Some people may need to take bisphosphonates for longer than three or five years. After three to five years, your doctor will review your symptoms and decide whether you need to take bisphosphonates or not. They may recommend taking a different type of medicine to prevent fractures.
If you are taking bisphosphonates, you should watch for signs of osteonecrosis, which is when the bone dies. This usually happens when the jawbone does not get enough blood. In this condition, the bone may also become infected. If you are taking bisphosphonates, be sure to tell your doctor if you have stomach ulcers, duodenal ulcers, or other structural problems of the esophagus.
Bisphosphonates can also cause muscle pain. The pain may be uncomfortable, but it will go away after you stop taking bisphosphonates.
Prevention of Osteoporosis
Taking bisphosphonates is one of the most popular treatments for osteoporosis. These drugs work by inhibiting the bone resorption process, which leads to the buildup of new bone. The effect of these drugs lasts for years and helps maintain bone architecture.
The risk of fractures is high when osteoporosis is left untreated. The cost of osteoporotic fractures is significant and the disease is associated with a high rate of morbidity and mortality.
Bisphosphonates are prescribed to postmenopausal women to prevent osteoporosis-related fractures. These drugs work by inhibiting the bone-resorbing process and increasing the density of bone. The use of bisphosphonates can also help reduce the risk of future fractures caused by aging and estrogen deficiency.
Three studies have shown that bisphosphonates reduce the risk of fractures in elderly women. The rate of fractures in these studies was significantly less in the treatment group than in the placebo group.
A fourth study looked at the fracture rates of 66 postmenopausal women with osteoporosis. The rate of fractures in the treatment group was 1.2%. The rate of fractures in the control group was 10.4%. The authors of the fourth study found that there was a higher rate of fractures in the placebo group.
The use of bisphosphonates requires patients to be evaluated before treatment and the doctor will weigh the risks and benefits of the medication. If the patient has certain risk factors, the doctor may recommend discontinuing bisphosphonate therapy.
Bisphosphonates are generally taken for three to five years. Some people may need a longer period of treatment.
Before starting bisphosphonate therapy, people should have dental cleanings. This will help ensure that the area of the jaw where the medication is being used is free from infection.
Treatment of myeloma
Various bisphosphonates are prescribed in the treatment of multiple myeloma, which is a type of cancer that grows in the bone marrow and causes the bones to become brittle. These drugs are used to control bone pain, reduce the risk of vertebral fractures, and prevent bone-related events. However, they are also associated with side effects and may be harmful in some patients.
Bisphosphonates inhibit the activity of osteoclasts, which are a group of bone cells that destroy the bone. They are also known to have antitumor effects in vitro and in vivo against myeloma cells. However, they do not have an advantage over other palliative treatments.
In the treatment of myeloma, bisphosphonates are generally given by intravenous infusion. The main type used is zoledronic acid. The drug is given monthly, for at least 12 months. It may also be taken in tablet form.
Zoledronic acid is the preferred bisphosphonate for multiple myeloma patients. It affects the serum osteoprotegerin level and may have a possible antimyeloma effect. However, the effects of zoledronic acid on overall survival and progression-free survival are not yet well established.
Some studies have shown that bisphosphonates increase the risk of renal toxicity. These studies have led to changes in clinical practice. They have also indicated that patients should be monitored for osteolytic bone disease, which is a common feature of multiple myeloma.
Bisphosphonates may also be associated with osteonecrosis of the jaw. This type of osteonecrosis is a severe and debilitating condition. It can lead to difficulty in opening and closing the jaw. In addition, it can cause bone pain and may lead to numbness or tingling in the hands or feet.
Bisphosphonates are pyrophosphate analogs that have a high affinity for bone. They are commonly given by intravenous infusion and are recommended by major organizations, such as the American Society of Clinical Oncology.
Treatment of secondary breast cancer
Several bisphosphonates have been approved for use in breast cancer patients with metastatic bone disease. These drugs work by preventing hypercalcemia and inhibiting tumor resorption. They can also reduce the risk of fractures and spinal cord compression. Bisphosphonates can also improve the quality of life of patients.
Bisphosphonates are used in both adjuvant and post-operative settings. Studies have examined bisphosphonates’ effects on cancer metastasis and overall survival in women with breast cancer. Compared to patients who were not given bisphosphonates, women who received bisphosphonates had a lower risk of fractures and better quality of life.
Several studies have examined the cost-effectiveness of bisphosphonates. However, the results are mixed. The results vary depending on the type of bisphosphonate and the population studied. Some studies show that bisphosphonates have a significant cost-effectiveness benefit while others show conflicting results. The cost-effectiveness of bisphosphonates should be considered when making treatment decisions.
Bisphosphonates are effective in preventing hypercalcemia and reducing bone pain. They also inhibit tumor adhesion and neo-angiogenesis. Bisphosphonates have been approved for many types of cancer. They can be administered by both oral and intravenous routes.
Oral bisphosphonates may have inferior efficacy and poor adherence. A recent survey of oncologists showed that a majority of oncologists expect adherence rates for IV bisphosphonates to be better than for oral drugs.
In a study of clinical oncologists in the UK, 40 percent of oncologists prescribed IV drugs only. Some oncologists believe that patients prefer the convenience of oral drugs. A questionnaire asked clinicians to rate the advantages and disadvantages of oral bisphosphonates. It also asked them to identify the most commonly prescribed bisphosphonates. The majority of oncologists cited a number of advantages: convenience, no IV access, bioavailability, and general convenience.
Treatment of secondary prostate cancer
Several bisphosphonates have been studied for their potential use in the treatment of secondary prostate cancer. These include zoledronate, clodronate, and risedronate. These agents are used in men with bone metastases from prostate cancer and may also be useful in men with castration-sensitive prostate cancer.
Zoledronic acid is the most commonly used bisphosphonate in clinical practice. The ZEUS trial evaluated zoledronic acid (4 mg every three months) in 1433 men with high-risk localized prostate cancer. Although the study found no increase in bone metastasis-free survival, it was limited by a lack of supporting data.
Bisphosphonates also have been studied in patients with secondary breast cancer. They may increase bone mineral density (BMD) and prevent skeletal-related events (SREs). However, bisphosphonates may also be used to prevent bone surgery, reduce vertebral fractures, and reduce radiation therapy to the bone.
Bisphosphonates are also recommended for the treatment of mildly symptomatic CRPC. However, they are not recommended for patients with high-risk localized prostate cancer. They may also be useful in patients with bone metastases from prostate cancer, but the evidence is weak.
Denosumab is a RANKL inhibitor. It is considered beneficial for patients with castration-sensitive prostate cancer and may slow bone metastases in patients with CRPC. However, denosumab is more expensive than zoledronic acid. It may also cause more severe cases of hypocalcemia.
Bisphosphonates are not recommended for the treatment of non-metastases. However, if they are used in prostate metastases, they may provide substantial pain relief.
Although bisphosphonates are beneficial in the treatment of secondary prostate cancer, the safety profile of these agents must be considered when they are prescribed. The use of these agents in the management of prostate cancer is complicated by an evolving treatment landscape.
Health Sources:
Health A to Z. (n.d.). HSE.ie. https://www2.hse.ie/az/
U.S. National Library of Medicine. (n.d.). https://www.ncbi.nlm.nih.gov/
Directory Health Topics. (n.d.). https://www.healthline.com/directory/topics
Health A-Z. (2022, April 26). Verywell Health. https://www.verywellhealth.com/health-a-z-4014770
Harvard Health. (2015, November 17). Health A to Z. https://www.health.harvard.edu/health-a-to-z
Health Conditions A-Z Sitemap. (n.d.). EverydayHealth.com. https://www.everydayhealth.com/conditions/
